US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

BEAM Beam Therapeutics Inc

25.95

-1.33 (-4.88%)

2025年2月1日 - 終了

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Some of the shares covered by this filing are stock options that will be exercised within three months from the date of this filing. Sales that were executed on October 14, 2024 are being reported on this Form 144 filed today given the EDGAR system was not accepting filings on October 14, 2024 in observance of the federal holiday.

Date of Notice

10/15/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

06/28/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Giuseppe Ciaramella

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Beam Therapeutics (NASDAQ:BEAM)
過去株価チャート
から 1 2025 まで 2 2025

Beam Therapeuticsのチャートをもっと見るにはこちらをクリック

Beam Therapeutics (NASDAQ:BEAM)
過去株価チャート
から 2 2024 まで 2 2025

Beam Therapeuticsのチャートをもっと見るにはこちらをクリック

ニュース - Beam Therapeutics Inc

Form 144 - Report of proposed sale of securities
金曜日 31年1月2025日 (1日前) • Edgar (US Regulatory)

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
木曜日 30年1月2025日 (2日前) • GlobeNewswire Inc.

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
木曜日 23年1月2025日 (1週前) • GlobeNewswire Inc.

Form 8-K - Current report
月曜日 13年1月2025日 (3週前) • Edgar (US Regulatory)

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
月曜日 13年1月2025日 (3週前) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
火曜日 7年1月2025日 (4週前) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
火曜日 7年1月2025日 (4週前) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
金曜日 3年1月2025日 (4週前) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
火曜日 31年12月2024日 (1月前) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
火曜日 31年12月2024日 (1月前) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
金曜日 20年12月2024日 (1月前) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
金曜日 20年12月2024日 (1月前) • Edgar (US Regulatory)

その他のBeam Therapeutics Incニュース記事

Financial Select Sector

JP Morgan Chase

Invesco QQQ Trust Series 1

Verizon Communications

US Dollar vs Euro

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約